DiagnosTear Technologies Inc. Announces Private Placement of Units

Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services AI Disclosure Intelligence SEDAR+ About SEDAR+ SEDAR+ Resources EDGAR EDGAR Service Overview EDGAR Resources Webcasting and Conference Calling Newsroom Newsroom Newsroom Newswire Guidelines Sign Up for News Integrate Blog Contact DiagnosTear Technologies Inc. Announces Private Placement of Units August 31, 2026 7:00 AM EDT | Source: DiagnosTear Technologies Inc. Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) (" DiagnosTear " or the " Company ") is pleased to announce it will be proceeding with a non-brokered private placement of up to 2,800,000 units (" Units ") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$1,400,000 (the " Offering "). The Company expects BioLight Life Sciences Ltd., parent company of DiagnosTear, and Elcam Medical Ltd. to each participate for up to one-third of the total Offering. Each Unit will consist of one common share of the Company (a " Common Share ") and one common share purchase warrant (a " Warrant" ). Each Warrant will be exercisable to purchase one Common Share at an exercise price of C$1.00 for a term of twelve (12) months from the closing date of the Offering. No finder's fees will be paid in connection with this Offering. The net proceeds of the Offering will be used for the Company's working capital and general corporate purposes. All securities to be issued, subject to occurrence of the closing of the Offering, will be subject to a statutory hold period expiring four months and one day after the issuance thereof. Closing of the Offering is subject to approval of the Canadian Securities Exchange. Certain insiders of the Company may acquire Units in the Offering. Any participation by insiders in the Offering would constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (" MI 61-101 "). However, the Company expects such participation would be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, would exceed 25% of the Company's market capitalization. None of the securities sold in connection with the Offering will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors: Yifftach Biel, Chief Financial Officer DiagnosTear Technologies Inc. For further information, please contact: Dr. Shimon Gross, Chief Executive Officer DiagnosTear Technologies Inc. Email: shimon@diagnostear.com Tel: +972-523408550 About DiagnosTear DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear's TeaRx™ technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD, and Israeli MoH-approved test based on the TeaRx™ platform is intended for diagnosis of Dry Eye Syndrome (DES TeaRxTM Dry Eye). This product is not FDA-cleared yet. Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications. Among others, DiagnosTear's pipeline includes TeaRx™ Red Eye: The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis and Allergic conjunctivitis. For additional information about DiagnosTear, please visit https://diagnostear.com . Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historic